Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision
The FDA is delaying its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy for multiple myeloma in earlier lines …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
